UK Regulatory Position on GLP-1 Medicines and Cancer The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) maintain active surveillance of GLP-1 receptor agonists and have issued clear guidance regarding their safety profile, including cancer-related considerations
In human unselected lymphocytes and LPS-activated monocytes, 1,8-cineole inhibited the production of cytokines such as IL-4, IL-5, IL-1, and TNF- in lymphocytes
During mitochondrial biogenesis, the upstream signal regulators, silent information regulator 1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK), activate PGC-1 through phosphorylation and deacetylation modifications
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia